- Home
- NL vs TRVI Comparison
NL vs TRVI Comparison
Compare NL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NL
- TRVI
- Stock Information
- Founded
- NL 1891
- TRVI 2011
- Country
- NL United States
- TRVI United States
- Employees
- NL N/A
- TRVI N/A
- Industry
- NL Major Chemicals
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NL Industrials
- TRVI Health Care
- Exchange
- NL Nasdaq
- TRVI Nasdaq
- Market Cap
- NL 362.9M
- TRVI 383.4M
- IPO Year
- NL N/A
- TRVI 2019
- Fundamental
- Price
- NL $8.37
- TRVI $6.60
- Analyst Decision
- NL Sell
- TRVI Strong Buy
- Analyst Count
- NL 1
- TRVI 8
- Target Price
- NL $6.00
- TRVI $17.56
- AVG Volume (30 Days)
- NL 25.9K
- TRVI 1.3M
- Earning Date
- NL 05-07-2025
- TRVI 05-08-2025
- Dividend Yield
- NL 4.26%
- TRVI N/A
- EPS Growth
- NL 441.25
- TRVI N/A
- EPS
- NL 1.25
- TRVI N/A
- Revenue
- NL $148,242,000.00
- TRVI N/A
- Revenue This Year
- NL $15.75
- TRVI N/A
- Revenue Next Year
- NL $2.44
- TRVI N/A
- P/E Ratio
- NL $7.28
- TRVI N/A
- Revenue Growth
- NL N/A
- TRVI N/A
- 52 Week Low
- NL $5.20
- TRVI $2.30
- 52 Week High
- NL $9.42
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- NL 53.17
- TRVI 56.08
- Support Level
- NL $8.22
- TRVI $6.14
- Resistance Level
- NL $9.27
- TRVI $7.24
- Average True Range (ATR)
- NL 0.38
- TRVI 0.39
- MACD
- NL 0.04
- TRVI 0.01
- Stochastic Oscillator
- NL 50.27
- TRVI 50.39
About NL NL Industries Inc.
NL Industries Inc operates in the component products industry through its majority-owned subsidiary, CompX International Inc. It manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. CompX has three production facilities in the United States, through which it produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.